Research in npj Precision Oncology highlights multi-cohort training approach and accurate analysis ...
Lunit INSIGHT MMG integrated into the clinical workflow of Australia's BreastScreen New South Wales...
Lunit and Volpara revealed a unified Ecosystem at RSNA 2024, featuring AI-powered cancer risk predi...
Follow-up to ScreenTrustCAD presented at RSNA 2024 highlights 1-year post-AI adoption success in im...
* AI-powered chest X-ray and mammography analysis solutions to be deployed across one ofMexico's ...
Twenty studies validate AI performance across diverse populations and clinical settings, including ...
Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-...
Agreement to make Lunit INSIGHT MMG accessible to over 400 sites across France SEOUL, South Korea, ...
Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment out...
* Two new studies show Lunit INSIGHT MMG cuts radiologist workload by 50% in a double reading env...
* Lunit SCOPE IO® demonstrates potential to assess immune phenotype as an AI-powered biomarker fo...
* Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pa...
* AI-based tumor microenvironment classification utilizing Lunit SCOPE IO® shows promise for guid...
* Lancet Digital Health study highlights Lunit INSIGHT CXR as top performer in TB screening, show...
* Middle East's first full-scale AI adoption for national screening marks Lunit's latest mileston...
- Lunit's ASCO 2024 presentations to highlight advances including HER2 ultra-low detection and AI-p...
SEOUL, South Korea, May 22, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-po...
- From research to real-world impact: Lunit demonstrates Lunit INSIGHT's clinical safety, effective...
- Employing Lunit INSIGHT MMG, a Turkish study showcases 70% efficiency improvements, advancements ...
- Lunit's AACR 2024 presentations to spotlight HER2 mutation insights and CNTN4's role in immunothe...
